Currently Viewing:
Supplements The Great Debate Part II: Should Managed Care Rely on Cost Sharing to Manage Big-ticket Biologics?
The Debate
The Great Debate Part II
Diana I. Brixner, RPh, PhD; Leslie Fish, RPh, PharmD; and Wayne M. Lednar, MD, PhD
The Case for Cost Sharing for Biologic Therapies
Leslie Fish, RPh, Pharm D
The Case Against Excessive Cost Sharing
Diana I. Brixner, RPh, PhD
Balancing Quality Employee Benefits With Cost Sharing
Wayne M. Lednar, MD, PhD
The Great Debate Part II: Should Managed Care Rely on Cost Sharing to Manage Big-ticket Biologics?
Mark Zitter, MBA
Currently Reading
CE/CME Quiz

CE/CME Quiz

Method of Participation:

Participants must:

  • Read the learning objectives and faculty disclosures.
  • Study the educational activity.
  • Complete and submit the post-test with a pass rate of 70% or higher.
  • Complete and submit the evaluation forms.
  • Complete and submit the attendance verification form.

A statement of credit will be issued only upon receipt of completed evaluation forms, a completed post-test with a score of 70% or higher, and a completed attendance verification form. Your statement of credit will be e-mailed to you 6 to 8 weeks after receipt.

Instructions

After reading "The Great Debate Part II: Should Managed Care Rely on Cost Sharing to Manage Big-ticket Biologics?" please complete the program evaluation and circle the 1 best answer to each of the following questions.

1. Any degree of copayment suppresses demand not only for inappropriate care, but also for necessary therapy.

  1. True
  2. False

2. There is a link between the degree of health literacy and activation a patient has and how healthy they are.

  1. True
  2. False

3. Some ways in which the value of a therapy can be shown to patients include:

  1. Offering educational information about the drugs.
  2. Providing a clear explanation of all costs.
  3. Conveying value in terms understandable by patients.
  4. All of the above

4. Cost is usually one of the most cited reasons why patients discontinue needed therapy.

  1. True
  2. False

5. Remission in patients with Crohn's disease is associated with improvement in the following:

  1. Patient's employment
  2. Quality of life
  3. All of the above

6. Increasing patient cost sharing is the most effective way to reduce healthcare costs while maintaining access to needed therapies.

  1. True
  2. False

7. The primary goal of patient cost sharing is:

  1. Reduction in overall pharmaceutical costs paid by health insurance.
  2. Reduction of inappropriate utilization.
  3. Reduction in health insurance premiums paid by employers.
  4. All of the above

8. Currently the fastest growing component of healthcare costs in the United States is:

  1. Hospital costs.
  2. Physician costs.
  3. Pharmaceutical costs.

9. Employers are concerned with ____ when evaluating healthcare coverage decisions for their employees.

  1. Cost
  2. Ability of a therapy to help an employee return to work (disability)
  3. Ability of a therapy to help an employee be productive at work (presenteeism)
  4. All of the above

10. The majority of healthcare cost increases in the United States are related to pharmaceutical products.

  1. False
  2. True



GOAL

To enhance understanding of the challenges faced by managed care and employers when balancing access to expensive therapies with cost.

TARGET AUDIENCE

Managed care pharmacy directors, medical directors, and other managed care executives responsible for overseeing the use of biologics and managing them on behalf of health plans.

LEARNING OBJECTIVES

After completing this activity, participants should be able to:

  • Explain the managed care trends related to cost sharing for biologic therapies.
  • Describe the managed care challenges associated with making biologic therapies available to the appropriate patients.
  • Know the correlation between increased cost sharing and decreased adherence to therapy.
  • Understand the balance that employers maintain between healthcare costs and productivity.

Initial Live Release Date: October 7, 2005

Release Date: April 1, 2006

Expiration Date: March 31, 2007

If the participant has previously attended this program and requested or received credit, he/she may not request or receive credit for the home study version of the program.

FEES

There are no fees associated with this continuing education offering.

FUNDING

Genentech has provided the grant funds for this activity.

Credit Designation:

The University of Utah College of Pharmacy designates this continuing education activity for 1.5 credit hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Program Number: 068-999-05-042-H04.

The University of Utah College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The University of Utah School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Utah School of Medicine designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Utah College of Pharmacy and the University of Utah School of Medicine do not recommend the use of any agent outside of the labeled indications.

MEDIA

Journal article learning activity.

PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up